3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
12
NET
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Fluorodeoxyglucose F18
3
Trastuzumab
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
FAPI-46
2
Everolimus
2
tipifarnib
1
sargramostim
1
regorafenib
1
lanreotide
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
exemestane
1
entinostat
1
cabozantinib
1
aldesleukin
1
Tirapazamine
1
Tamoxifen
1
Surveys and Questionnaires
1
Sorafenib
1
Rose Bengal
1
Radiotherapy
1
Radiosurgery
1
Radiofrequency Ablation
1
Quality of Life
1
Oxaliplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
gadolinium ethoxybenzyl DTPA
×
Endocrine
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled